Unlock Europe’s Diverse Healthcare Landscapes
Europe is not one market—it’s a mosaic of systems, processes, and priorities. Success depends on your ability to adapt your strategy for each country while maintaining a strong, consistent value message. At Kintiga, we combine deep knowledge of national payer environments with therapeutic area expertise to shape strategies that meet local requirements and resonate with decision-makers. From crafting robust value dossiers to preparing for price and reimbursement negotiations, we ensure your product is positioned to succeed in every jurisdiction.
Our services cover:
- HTA readiness assessments and strategic gap analysis
- Global pricing strategy and analysis
- Country specific roadmaps and submissions planning (including reimbursement strategy)
- Preparation of full local submissions (locally adapted in line with local procedures)
- Structured Expert Elicitation through acknowledged methods
- Expert insights gathering & patient journey mapping
- Payer advisory boards and expert engagement
- Strategic support, preparation, simulation, and assumption of negotiation leadership in price negotiations
- Price negotiation support in local market and hands on support during negotiations (e.g., CEPS in France, GKV-SV in Germany, AIFA in Italy)
- Local adaptation of core value dossier and HEOR deliverables
Our services
We combine expertise in full market access strategy and support, value communications, HEOR, policy & public affairs, legal counsel, regulatory compliance, and medical expertise across our services, creating a synergy that ensures your strategies and value dossier fully capture your technology’s value.
European HTAs are complex, with strict timelines, but with our deep local expertise, you can be confident your submissions are right the first time and fully meet payer expectations.
We support with:
- Readiness assessments and strategic organisational planning.
- Gap analysis and evidence generation
- Commercial strategy and negotiations
- Cost-effectiveness and budget impact modelling
- Systematic Literature Reviews (SLRs) and Global Value Dossiers (GVDs)
- Comprehensive training on procedures and practical guidelines
- Mock Committee Meetings
- HTA submissions
Misaligned messaging or inconsistent evidence can undermine even the best therapies. We know how vital it is to create a clear, compelling narrative that reflects your innovation’s full value.
By combining insights from market access, HEOR, strategic pricing, policy and public affairs, we ensure your asset’s value is captured in a cohesive, persuasive dossier.
We support with:
- Evidence generation including systematic literature reviews and HEOR analyses
- Stakeholder engagement
- PIM and EAMS applications
- Global value dossier development
We understand the pressure of balancing payer expectations, patients’ needs, and business goals, partnering with you to ensure your pricing is both sustainable and impactful.
We support with:
- Comprehensive payer negotiation support
- Pricing research and modelling, market landscaping and cost-effectiveness assessments
- Launch sequencing through international reference pricing
- Stakeholder insight gathering
- Payer research
- Performance-based reimbursement models, risk-sharing or cap models
- Contract negotiations with regional health insurers across Europe
- Complex therapies, such as gene therapies and ATMPs
Data gaps and payer demands can make market access can be arduous. At Kintiga, we help you create robust evidence that resonates with stakeholders.
We support with:
- Health economic and budget impact modelling (BIM), from early analysis and model review to full model development.
- Evidence generation and gap analysis
- Payer landscape insights
- Custom models and insights for local market local markets
- Treatment pathway and model input validation
- HTA modelling
Navigating stakeholder dynamics is a labourious process without the right support. We help you connect with payers, regulators and other key players early in the process, ensuring their perspectives shape every aspect of your approach towards sustained patient access.
We support with:
- Advisory boards
- Delphi panels
- Expert elicitation research
- Scientific stakeholder management, including Medical Science Liaison (MSL) coordination
- Building and maintaining relationships with external stakeholders
